IRadimed Corporation (IRMD)
| Market Cap | 354.48M |
| Revenue (ttm) | 32.26M |
| Net Income (ttm) | 986,639 |
| Shares Out | 12.31M |
| EPS (ttm) | 0.08 |
| PE Ratio | 355.43 |
| Forward PE | 48.31 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $28.79 |
| Previous Close | $28.95 |
| Change ($) | -0.16 |
| Change (%) | -0.55% |
| Day's Open | 28.97 |
| Day's Range | 28.31 - 28.80 |
| Day's Volume | 4,058 |
| 52-Week Range | 20.46 - 29.98 |
iRadimed (IRMD) delivered earnings and revenue surprises of 44.44% and 10.34%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
WINTER SPRINGS, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices...
iRadimed (NASDAQ:IRMD) announces its next round of earnings this Friday, April 30. Here is Benzinga's look at iRadimed's Q1 earnings report.
WINTER SPRINGS, Fla., April 09, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 first quarter financial results before the market open...
WINTER SPRINGS, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market open...
The S&P 500 Index stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of 1.97% per annum over the past five years, which occurred alongside ...
IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2020 Results - Earnings Call Transcript
IRadimed Corporation's (IRMD) CEO Roger Susi On Q3 2020 Results - Quick Version Earnings Call Transcript
iRadimed (IRMD) delivered earnings and revenue surprises of 120.00% and 3.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WINTER SPRINGS, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices ...
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WINTER SPRINGS, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 third quarter financial results before the market opens...
IRadimed Corp (IRMD) CEO Roger Susi on Q2 2020 Results - Earnings Call Transcript
iRadimed (IRMD) delivered earnings and revenue surprises of 225.00% and 22.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WINTER SPRINGS, Fla., July 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical device...
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WINTER SPRINGS, Fla., July 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 second quarter financial results before the market op...
WINTER SPRINGS, Fla., May 29, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s P...
Latest patent expands previous claims around IRADIMED’s wireless communication as used to remotely control an IV pump Latest patent expands previous claims around IRADIMED’s wireless communication as us...
IRadimed's (IRMD) CEO Leslie McDonnell on Q1 2020 Results - Earnings Call Transcript
iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of iRadimed (NASDAQ:IRMD) rose 0.2% after the company reported Q1 results.
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Expects first quarter 2020 revenue of $8.6 million to $8.7 million Expects first quarter 2020 revenue of $8.6 million to $8.7 million
IRadimed's (IRMD) CEO Leslie McDonnell on Q4 2019 Results - Earnings Call Transcript
iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WINTER SPRINGS, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced the retirement of Brent Johnson, Executive Vice President of Worldwide Sales and Marketing, effect...
These companies are somewhere past proof of concept and on the road to profitability or already profitable.
WINTER SPRINGS, Fla., Dec. 12, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only k...
IRADIMED Corporation (IRMD) CEO Leslie McDonnell on Q3 2019 Results - Earnings Call Transcript
iRadimed (IRMD) delivered earnings and revenue surprises of 53.33% and 1.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
WINTER SPRINGS, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only k...
IRMD will soon report record revenue and improving margins for a fourth consecutive quarter.
WINTER SPRINGS, Fla., Oct. 08, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving al...
IRadimed is a leader in developing innovative MRI (Magnetic Resonance Imaging) compatible medical devices and accessories.
WINTER SPRINGS, Fla., Aug. 27, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chie...
IRadimed Corp (IRMD) CEO Roger Susi on Q2 2019 Results - Earnings Call Transcript
IRMD is the only known provider of non-magnetic MRI compatible products in the U.S.
IRadimed Corp (IRMD) CEO Roger Susi on Q1 2019 Results - Earnings Call Transcript
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensor... [Read more...]
| Industry Medical Devices | IPO Date Jul 16, 2014 |
| CEO Leslie McDonnell | Employees 110 |
| Stock Exchange NASDAQ | Ticker Symbol IRMD |
Financial Performance
In 2020, IRadimed's revenue was $31.72 million, a decrease of -17.65% compared to the previous year's $38.52 million. Earnings were $1.37 million, a decrease of -85.79%.
Analyst Forecasts
According to one analyst, the rating for IRadimed stock is "Buy" and the 12-month stock price forecast is 33.00.